Pituitary adenylate cyclase-activating peptide (PACAP) (6-27) is a PACAP receptor antagonist with IC50 values of 1,500, 600, and 300 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors on SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 24.5, 106, and 105 nM, respectively) and inhibits cAMP accumulation induced by PACAP (1-38) (Kis = 457, 102, and 283 nM, respectively, in SH-SY5Y, SK-N-MC, and T47D cells). In vivo, in newborn pigs, PACAP (6-27) (10 μM) inhibits vasodilation of pial arterioles induced by PACAP (1-27) and PACAP (1-38) . It also inhibits PACAP (1-27)-stimulated increases in plasma insulin and glucagon levels and pancreatic venous blood flow in dogs when administered locally to the pancreas at a dose of 500 μg.
CP-628006 is a small molecule CFTR potentiator that effectively restores ATP-dependent channel gating to G551D-CFTR, the mutant form found in cystic fibrosis.
VIP(6-28)(human, rat, porcine, bovine) is a potent antagonist that effectively counteracts the effects of exogenous vasoactive intestinal peptide (VIP) on cyclic adenosine monophosphate (cAMP) signaling.
Dusquetide TFA is a kind of innate defense regulator (IDR).Dusquetide TFA has been shown to be active in reducing inflammation and increasing clearance of bacterial infections.Dusquetide TFA regulates innate immune responses to PAMPs and DAMPs in combinat
YT 6-2 是一种针对p62 SQSTM1的自噬靶向配体 (ATL),适用于合成AUTOTAC降解剂ATC-324。ATC-324 通过促进 AR p62 复合物的形成,使 AR 经由自噬-溶酶体途径降解。它能够降低核内 AR 水平,下调 AR 和 AR-v7 相关靶基因的表达,并对前列腺癌(PCa)中常见的 AR 突变体产生降解效果。